ARTICLE | Clinical News
RPR/INGN 201: Began Phase III trial
June 12, 2000 7:00 AM UTC
Introgen Therapeutics Inc., Austin, Texas Product: RPR/INGN 201 Business: Cancer Therapeutic category: Gene therapy, Cell proliferation Target: Tumor cells Description: Adenoviral p53 tumor suppressor...